BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced its financial results for the first quarter of 2007. For the three months ended March 31, 2007, Enzon reported a net loss of $1.9 million or $0.04 per diluted share, as compared to net income of $21.7 million or $0.50 per diluted share for the same quarter in 2006. First quarter results in 2006 were favorably impacted by the $13.8 million gain from the sale of marketable securities.
